Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Exploring the Role of Diagnostic Biochemistry
share announcement

Exploring the Role of Diagnostic Biochemistry

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2713

Special Issue Editors

Prof. Dr. Daria Pašalić

E-Mail Website
Guest Editor
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Zagreb University School of Medicine, Zagreb, Croatia
Interests: clinical biochemistry; molecular diagnostics; genetics; epigenetics
Prof. Dr. Lidija Bilic-Zulle

E-Mail Website
Guest Editor
Clinical Department of Laboratory Diagnosis, Clinical Hospital Center Rijeka, Rijeka, Croatia
Interests: clinical biochemistry; health informatics; clinical laboratory science; laboratory analysis

Special Issue Information

Dear Colleagues,

Biochemical testing is used in clinical medicine to obtain biochemical information for the treatment of patients. Information can only be used effectively for clinical decision making if it is true and appropriate, and if the physician recognizes how important it is. Among other kinds of diagnostics, laboratory tests are included in almost 80% of clinical decisions. Therefore, patient safety in laboratory medicine must be thoroughly assured. It needs to be acknowledged as a guarantee against any potential mistakes in the total testing process. Biochemistry is therefore essential in the diagnosis and management of different disorders.

Prof. Dr. Daria Pašalić
Prof. Dr. Lidija Bilic-Zulle
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • laboratory tests in diagnosis, prognosis, monitoring, and treatment
  • blood biomarkers in laboratory medicine
  • extravascular body fluid biomarkers in laboratory medicine
  • novel biomarkers in clinical biochemistry
  • evidence-based laboratory medicine
  • extra analytical phase and patient safety
  • quality assurance and management in laboratory medicine

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2938 KiB  
Article
Releasing Dynamic of Serum ST2 and Calprotectin in Patients with Acute Ischemic Stroke
by Ana Sruk, Hrvoje Budinčević, Ana-Maria Šimundić, Lora Dukić, Tena Sučić Radovanović, Helena Čičak and Daria Pašalić
Diagnostics 2024, 14(13), 1331; https://doi.org/10.3390/diagnostics14131331 - 23 Jun 2024
Viewed by 438
Abstract
This study investigated the releasing dynamics of serum ST2 and calprotectin in patients with acute IS. The study included acute IS patients (N = 20) with an NIH Stroke Scale score ≥8. Sampling was performed at seven time points: after admission (T0) and [...] Read more.
This study investigated the releasing dynamics of serum ST2 and calprotectin in patients with acute IS. The study included acute IS patients (N = 20) with an NIH Stroke Scale score ≥8. Sampling was performed at seven time points: after admission (T0) and at the following 24 h consecutive intervals (T1–T6). Primary outcome at 90 days was evaluated using the modified Rankin scale: 0–2 for good and 3–6 for poor functional outcome. The secondary outcome was all-cause mortality after 90 days. Fifteen patients had a poor outcome, and eight died. Results showed a statistically significant difference in ST2 concentrations between good and poor outcomes at T0 (p = 0.04), T1 (p = 0.006), T2 (p = 0.01), T3 (p = 0.021), T4 (p = 0.007), T5 (p = 0.032), and for calprotectin T6 (p = 0.034). Prognostic accuracy was highest for ST2 at T1 for a cut-off > 18.9 µg/L (sensitivity 80% and specificity 100.0%) and for calprotectin at T5 for a cut-off > 4.5 mg/L (sensitivity 64.3% and specificity 100.0%). Serum ST2 and calprotectin-releasing dynamics showed a valuable prognostic accuracy for IS outcomes. Full article
(This article belongs to the Special Issue Exploring the Role of Diagnostic Biochemistry)
►▼ Show Figures

Figure 1

13 pages, 1069 KiB  
Article
Comparison between the Friedewald, Martin and Sampson Equations and LDL-C Quantification by Ultracentrifugation in a Mexican Population
by Giovanny Fuentevilla-Álvarez, María Elena Soto, José Antonio García Valdivia, Yazmín Estela Torres-Paz, Reyna Sámano, Israel Perez-Torres, Ricardo Gamboa-Ávila and Claudia Huesca-Gómez
Diagnostics 2024, 14(12), 1241; https://doi.org/10.3390/diagnostics14121241 - 13 Jun 2024
Viewed by 559
Abstract
Low-density lipoprotein cholesterol (LDL-C), which makes up about 70% of the cholesterol in the blood, is critical in the formation of arteriosclerotic plaques, increasing the risk of heart disease. LDL-C levels are estimated using Friedewald, Martin and Sampson equations, though they have limitations [...] Read more.
Low-density lipoprotein cholesterol (LDL-C), which makes up about 70% of the cholesterol in the blood, is critical in the formation of arteriosclerotic plaques, increasing the risk of heart disease. LDL-C levels are estimated using Friedewald, Martin and Sampson equations, though they have limitations with high triglycerides. Our aim is to compare the effectiveness of these equations versus the ultracentrifugation technique in individuals with and without dyslipidemia and identify precision. There were 113 participants, 59 healthy controls and 54 dyslipidemic patients. Samples were collected after fasting. LDL-C was estimated using the Friedewald, Martin and Sampson equations. The purified LDL-C, ultracentrifugated and dialysized control group without dyslipidemia vs. patients with coronary artery disease (CAD) showed differences in age, HDL-C, triglycerides and glucose non-HDL-C (p = 0.001 in all). There were correlations in CGWD between ultracentrifugation and Sampson R-squared (R2) = 0.791. In the dyslipidemia control group, ultracentrifugation and Friedewald R2 = 0.911. In patients with CAD, correlation between ultracentrifugation and Sampson R2 = 0.892; Bland–Altman confirmed agreement in controls without dyslipidemia. The Martin and Sampson equations are interchangeable with ultracentrifugation. Conclusion: The role of LDL analysis using precise techniques is necessary to obtain better control of disease outcomes after the use of precise therapies and suggests verifying its importance through clinical trials. Full article
(This article belongs to the Special Issue Exploring the Role of Diagnostic Biochemistry)
►▼ Show Figures

Figure 1

14 pages, 2499 KiB  
Article
Clinical and Analytical Comparison of Monoclonal and Polyclonal Immunoassays for Fecal Pancreatic Elastase
by Jasna Lenicek Krleza, Merica Aralica, Lara Milevoj Kopcinovic and Renata Zrinski Topic
Diagnostics 2024, 14(11), 1166; https://doi.org/10.3390/diagnostics14111166 - 31 May 2024
Viewed by 374
Abstract
Background: Numerous immunoassays have been commercialized to determine pancreatic elastase (PE) in feces in screening for exocrine pancreatic insufficiency (EPI), but how the different assays compare to one another is controversial, especially in the context that all methods use the same cut-off values [...] Read more.
Background: Numerous immunoassays have been commercialized to determine pancreatic elastase (PE) in feces in screening for exocrine pancreatic insufficiency (EPI), but how the different assays compare to one another is controversial, especially in the context that all methods use the same cut-off values for interpreting the results obtained on the presence or absence of EPI or the degree of insufficiency if it is present. Our aim was to analytically verify a new method for determining PE, compare the results with a previous method, and verify the declared cut-off values for interpretation of the results. Methods: PE in the stool was assayed using a previous monoclonal enzyme-linked immunosorbent assay (“ScheBo ELISA”) and a new polyclonal particle-enhanced turbidimetric immunoassay (“Bühlmann PETIA”). The direct method comparison of two immunoassays was performed in 40 samples. Clinical comparisons were conducted against each other for the binary determination of “abnormal/normal” elastase levels and the three-way determination of “severe/moderate/no” EPI in 56 samples. The indirect comparison method used external quality assessment (EQA) data to compare the monoclonal and polyclonal immunoassays for PE, and additionally compare the monoclonal ScheBo ELISA to a monoclonal chemiluminescence immunoassay (“DiaSorin CLIA”). Results: Precision in the series and intra-laboratory precision for Bühlmann PETIA met the manufacturer’s specifications for the concentration range of limit/lower values and the range of normal values. The Bühlmann PETIA immunoassay on different analytical platforms yielded comparable results and nearly perfect agreement in the case of three-way classification (kappa = 0.89 with 95%CI from 0.79 to 1.00. ScheBo ELISA tends to generate higher values of pancreatic elastase than the Bühlmann PETIA; agreement between the methods was moderate in the case of binary classification (kappa = 0.43; 95% CI 0.25 to 0.62), and substantial in the case of three-way classification (kappa = 0.62; 95% CI 0.50 to 0.75). EQA data analysis showed a statistically significant difference between ScheBo ELISA and Bühlmann PETIA peer groups (p = 0.031), as well as the DiaSorin CLIA and ScheBo ELISA peer groups (p = 0.010). Conclusion: The ScheBo ELISA and Bühlmann PETIA do not appear to be commutable in the analytical and clinical context. Our data address a discordance between different mono- and polyclonal immunoassays for pancreatic elastase and the potential of misclassification using its universal cut-off values in screening suspected patients for exocrine pancreatic insufficiency. Full article
(This article belongs to the Special Issue Exploring the Role of Diagnostic Biochemistry)
►▼ Show Figures

Figure 1

12 pages, 1428 KiB  
Article
Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by Soon Kyu Lee, Soon Woo Nam, Jeong Won Jang and Jung Hyun Kwon
Diagnostics 2024, 14(5), 495; https://doi.org/10.3390/diagnostics14050495 - 25 Feb 2024
Viewed by 893
Abstract
The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled [...] Read more.
The long-term kinetics of quantitative HBsAg levels in HBV-infected patients treated with entecavir or tenofovir, as well as the role of quantitative HBsAg in predicting functional cure (HBsAg loss) and low HBsAg levels (<2 log IU/mL) remain unclear. Of some 1661 consecutively enrolled patients newly treated with entecavir or tenofovir, we analyzed 852 patients who underwent serial HBsAg level checks every 6–12 months. The primary outcomes included long-term kinetics in HBsAg levels and the rate of functional cure and achieving low HBsAg levels. Over a mean 6.3-year follow-up, the functional cure rate was 2.28% (n = 19), and 12.9% (n = 108) achieved low HBsAg levels. A significant HBsAg level reduction was seen in the first treatment year (p < 0.05), with another stepwise decrease between year 6–7. These trends were pronounced in patients with chronic hepatitis and HBeAg-positivity compared to those with cirrhosis and HBeAg-negativity, respectively. Baseline HBsAg of ≤3 log IU/mL and the first-year HBsAg reduction were key predictors for both functional cure and low HBsAg levels (p < 0.05). In conclusion, our findings elucidate the stepwise reduction in quantitative HBsAg dynamics during high-potency NA therapy (entecavir or tenofovir) along with variations based on different conditions. We also underscore the significance of quantitative HBsAg titer in predicting functional cure and low-HBsAg levels. Full article
(This article belongs to the Special Issue Exploring the Role of Diagnostic Biochemistry)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop